My name is Stephanie Hawthorne and I am a doctoral candidate in the School of Education at Drexel University, Sacramento. I am hoping that you can help me. I am searching for volunteers to participate in my research study entitled HerStory: Narrative Accounts of Young African American Women with Eating Disorders. The purpose of my research is to understand the personal, social, and educational experiences of young African American women who have experienced diagnosed eating disorders during their adolescent years. This study is being conducted as part of Drexel University’s dissertation requirements for the Doctoral degree in Education under the supervision of Dr. Kathy Geller, Associate Clinical Professor.
To be eligible to participate in this study, potential participants need to meet the following criteria: 1) self-describe as an African American woman between the ages of 18 and 30; 2) be clinically diagnosed with an eating disorder during her adolescent years (between the ages of nine and 18); and 3) currently being or have been previously treated for an eating disorder.
Do you know of someone who may meet the above-mentioned criteria? Please have them email (*protected email*) or phone (916-628-8490) me directly. Thank you for your contribution to such a noteworthy issue.
Let me know of any questions you may have.
Very Respectfully,
Stephanie Hawthorne
Doctoral Candidate
Drexel University, Sacramento
*protected email*
916-628-8490
Purpose
The purpose of the study is to test a newly developed individual psychotherapy treatment for binge eating disorder in adults. This treatment is a type of individual psychotherapy called Integrative Cognitive-Affective Therapy (ICAT) that focuses on helping people change their behaviors, feelings, thoughts about themselves, and relationships. This new treatment is being compared to an existing treatment called Cognitive-Behavior Therapy-Guided Self Help (CBTgsh), which focuses on changing behavior patterns through the use of reading and homework assignments along with sessions with a therapist. The primary hypothesis of this investigation is that ICAT will be associated with greater reductions in binge eating at end of treatment and follow-up compared to CBTgsh.
Eligibility
Ages Eligible for Study: 18 Years to 65 Years
Genders Eligible for Study: Both
Accepts Healthy Volunteers: Yes
Criteria
Inclusion Criteria:
Binge eating disorder (DSM-5)
Exclusion Criteria:
History of gastric bypass surgery
Medical condition acutely affecting eating and/or weight
Current medical and/or psychiatric instability (e.g., acute suicidality)
Psychosis and/or bipolar disorder
Severe cognitive impairment or developmental disability
Inability to read English
Current substance use disorder
Current participation in psychotherapy and/or commercial weight loss program
Change in dosage and/or frequency of psychotropic medication in the past 6 weeks
Pregnant or breast feeding
BMI < 21
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT02043496
Contacts
Contact: Carol B Peterson, PhD 612-273-9811 ude.nmu@161retep
Contact: Stephen A Wonderlich, PhD 701-365-4910 moc.ografirn@hcilrednows
Locations
United States, Minnesota
University of Minnesota Recruiting
Minneapolis, Minnesota, United States, 55454
Contact: Carol B Peterson, PhD 612-273-9811 ude.nmu@161retep
Principal Investigator: Carol B Peterson, PhD
United States, North Dakota
Neuropsychiatric Research Institute Recruiting
Fargo, North Dakota, United States, 58107
Contact: Stephen A Wonderlich, PhD 701-365-4910 moc.ografirn@hcilrednows
Principal Investigator: Stephen A Wonderlich, PhD
Sponsors and Collaborators
University of Minnesota – Clinical and Translational Science Institute
Neuropsychiatric Research Institute, Fargo, North Dakota
Investigators
Principal Investigator: Carol B Peterson, PhD University of Minnesota – Clinical and Translational Science Institute
Principal Investigator: Stephen A Wonderlich, PhD Neuropsychiatric Research Institute/University of North Dakota
Purpose: This study will demonstrate the efficacy of Qsymia versus placebo in treating bulimia nervosa and binge eating disorder.
Detailed Description:
Bulimia nervosa (BN) and binge eating disorder (BED) are serious mental disorders associated with adverse psychological and physical consequences. Treatment options to date offer limited success, leaving at least 50-70% of patients still symptomatic after treatment. The purpose of the study is to evaluate whether phentermine-topiramate (Qsymia), a medication currently FDA approved for the treatment of obesity, will demonstrate efficacy—compared to placebo- when re-purposed for patients with bulimia and binge eating.
Participants will be randomized into one of two conditions: qsymia or Placebo. One condition will receive 3 months of phentermine-topiramate, a 2 week washout, then 3 months of placebo. The other condition will receive 3 months of Placebo, a 2 week washout, then 3 months of phentermine-topiramate. Participants will receive a total of 6 months of treatment and then have a 2 month follow-up off of medications.
Eligibility
Ages Eligible for Study: 18 Years to 60 Years
Genders Eligible for Study: Both
Accepts Healthy Volunteers: No
Criteria
Inclusion Criteria:
Must meet Diagnostic and Statistical Manual -Edition 5 criteria for bulimia or binge eating disorder, which has not responded to prior treatment
Men and women between the ages of 18-60
Must be at least normal weight (i.e. body mass index at least 21.0 or greater)
If female of child-bearing potential, the participant must have an initial negative pregnancy test and be taking adequate birth control
must be medically stable with no new diagnoses (medical, surgical, or psychiatric) within the past 6 months
Must be able to comply with study visits, treatment plans, and blood draws and other possible assessments (i.e. EKG)
Exclusion Criteria:
Any patient with bipolar disease or schizophrenia or any patient taking a mood stabilizer or antipsychotic medication within the past 3 months
Any patient with current or past history of anorexia nervosa (i.e., with a Body mass index of < 17.5).
Any patient with prior (within 30 days) use of Over The Counter (OTC) weight-reducing agents, herbal preparations
Any patient who has been prescribed a medication for weight loss within the past 3 months
Any psychological weight-loss interventions (i.e., Weight Watchers, Jenny Craig) in which patient has lost weight over the past month (unless willing to discontinue).
Any patient currently in therapy with a psychostimulant or who has used a psychostimulant within the past 6 months
Any patient with known sensitivity to phentermine or topiramate
Any patient who has had a change in thyroid, psychiatric, or blood pressure medications within the past one month
Any patient who is taking a potassium-wasting diuretic
Any patient who is on a carbonic anhydrase inhibitor such as zonisamide acetazolamide, or dichlorphenamide
Any diabetic who is taking insulin or an insulin secretagogue
Any patient with liver enzymes at baseline greater than three times the upper limit of normal
Any patient with a baseline potassium of less than 3.0 millequivalent/Liter. Patients with baseline potassium levels between 3.0-3.5 miliEquivalents/Liter will be encouraged to ingest high potassium foods such as bananas, oranges, or tomato juice daily during the study
Any patient with abnormal baseline thyroid test or with a Thyroid Stimulating Hormone (TSH) greater than 1.5 times the upper limit of normal
Any patient who is unwilling or expresses uncertainty about being able to refrain from daily alcohol use (even if at moderate levels) or illegal drugs while taking the study medication.
Any adult with recent history of suspected substance abuse of lifetime history of substance dependence
Any patient who regularly uses marijuana (including medical marijuana) or illegal drugs
Any patient who has a history of addiction to a stimulant
Any patient who expresses current suicidal ideation or who has a baseline Patient Health Questionnaire- 9 score of 10 or greater
Any patient with a history of nephrolithiasis
Any patient who is pregnant or who is planning to become pregnant during the study period.
Any patient who is currently participating in any other clinical study that involves an active treatment
Any patient who is unable to identify a primary care physician
Any patient with a history of cardiovascular disease (i.e. recent history of Myocardial Infarction, stroke, shortness of breath, chest pain) that could increase vulnerability to the sympathomimetic effects of a stimulant like drug. If clinical suspicion is high, baseline EKG will be obtained and anyone with abnormal findings will be excluded
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT02553824
Contacts
Contact: Debra L Safer, MD 650-723-7928 ude.drofnats@refasld
Contact: Sarah Adler, PsyD ude.drofnats@1relda
Locations
United States, California
Stanford School of Medicine, Psychiatry and Behavioral Sciences Recruiting
Stanford, California, United States, 94305
Contact: Debra L Safer, MD 650-723-7928 ude.drofnats@refasld
Sponsors and Collaborators
Stanford University
Investigators
Principal Investigator: Debra L Safer, MD Stanford University
More Information
Responsible Party: Debra L. Safer, Associate Professor, Stanford University
ClinicalTrials.gov Identifier: NCT02553824 History of Changes
Other Study ID Numbers: 31390
Study First Received: August 21, 2015
Last Updated: April 12, 2016
Health Authority: United States: Data and Safety Monitoring Board
United States: Institutional Review Board
Purpose
The purpose of this study is to examine biological (e.g., energy expenditure, neuroendocrine and appetitive hormones)and behavioral (e.g., binge eating and purging) correlates of weight suppression and current dieting status in women with bulimia nervosa. The investigators have differentiated between a diet-induced long-term energy imbalance (weight suppression, or the difference between one’s highest-ever body weight and current weight) and a short-term energy imbalance (current dieting to either lose weight or avoid weight gain). This study will elucidate how two common yet largely unexplored types of dieting influence biological and behavioral variables in patients with bulimia nervosa, which could lead to modifications of prevailing models of bulimia nervosa and new strategies for improving treatment outcome.
Detailed Description:
Bulimia nervosa (BN) is a debilitating psychiatric disorder that primarily affects young women. Empirically supported treatments for BN have been identified but less than half of treated individuals achieve long-term remission from the disorder, possibly because current treatment approaches do not sufficiently account for variables that help maintain the disorder. Psychosocial models of BN emphasize the role of dieting as a proximal cause of binge eating and purging. Dieting has both psychological and biological facets but existing models of BN have overwhelmingly focused on its psychological impact. The investigators have differentiated between a diet-induced long-term energy imbalance (weight suppression (WS), or the difference between one’s highest-ever body weight and current weight) and a short-term energy imbalance (current dieting to either lose weight or avoid weight gain). Recent research has shown that WS levels in BN are elevated and that degree of WS predicts the severity of various BN characteristics and its clinical course. Studies of current dieting (CD) to lose weight have found that it is associated with reduced binge eating in BN, a finding that conflicts with prevailing models of the disorder. The proposed research will examine biological (e.g., energy expenditure, neuroendocrine and appetitive hormones) and behavioral (e.g., binge eating and purging) correlates of WS and CD in those with BN. (Relatively few of those with BN report dieting to avoid weight gain but its biological and behavioral correlates will also be examined.) The project will recruit 132 women (66 at Drexel University and 66 at Columbia University) meeting provisional Diagnostic and Statistical Manual-V diagnostic criteria for BN. The investigators will test the hypotheses that 1) CD and elevated WS will be associated with alterations in biological indices of metabolism and appetite, 2) WS will predict greater binge eating and purging, and CD will predict less binge eating, measured using Ecological Momentary Assessment (EMA), and 3) higher real time ratings of daily food restriction intentions will predict a reduced probability of binge eating during the same day but an increased probability of binge eating in subsequent days. Assessments for all participants will include: weight and reported previous highest weight (to calculate WS), the Eating Disorders Examination, 14 days of EMA to assess food restriction intentions, binge eating and purging episodes, three 24-hr food recalls, and resting energy expenditure and metabolic and appetitive hormones (including complete thyroid panel, leptin, ghrelin, cortisol and estradiol). Participants will be asked to return 6 months later for follow-up assessments of weight. This study will elucidate how two common yet largely unexplored types of dieting influence biological and behavioral variables in patients with BN, which could lead to modifications of prevailing models of BN and new strategies for improving treatment outcome.
Eligibility
Ages Eligible for Study: 18 Years to 45 Years
Genders Eligible for Study: Female
Accepts Healthy Volunteers: No
Sampling Method: Non-Probability Sample
Study Population
Participants will be recruited from local university counseling centers and eating disorder centers.
Criteria
Inclusion Criteria:
Diagnosis of bulimia nervosa according to the proposed DSM-V criteria
Either currently receiving eating disorder treatment or actively seeking treatment
BMI above 18.5 and below 30
Not experiencing any signs of menopause
Medically stable as determined by each site’s study physician
Exclusion Criteria:
Change in pharmacological treatment over past 4 weeks
Currently taking atypical antipsychotic medications
History of anorexia nervosa within the past year
Pregnancy
Currently taking medications that could alter hormone levels or metabolism
Disorders affecting metabolism or hormone levels
Non-removal metallic object
Co-occurring severe mental illness
At risk for suicide
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01830374
Contacts
Contact: Jenny Gilbert, B.A. 215-553-7171 ude.lexerd@SDET
Locations
United States, New York
Columbia University Recruiting
New York, New York, United States, 10032
Contact: Esther Neustadt 215-543-5739 ude.aibmuloc.ipsyn@urde
Contact: Lindsay Kenney 215-543-5739 ude.aibmuloc.ipsyn@urde
Principal Investigator: Laurel Mayer, M.D.
United States, Pennsylvania
Drexel University Recruiting
Philadelphia, Pennsylvania, United States, 19104
Contact: Jenny Gilbert, B.A. 215-553-7171 ude.lexerd@SDET
Principal Investigator: Michael R. Lowe, Ph.D.
Sponsors and Collaborators
Drexel University
Columbia University
The Miriam Hospital
Investigators
Principal Investigator: Michael R. Lowe, Ph.D. Drexel University
Principal Investigator: Laurel Mayer, M.D. Columbia University
Are you the mother of a child who is currently receiving outpatient treatment for Anorexia Nervosa? If so, we’d like to invite you to participate in an anonymous study that examines the experience of caring for a child with Anorexia Nervosa. This study will look at how a child’s eating disorder affects the parents and family, and how families cope with caring for a child with Anorexia. We hope these research findings will provide greater insight into how a child’s illness affects families, so that more support services can be developed to help parents and caregivers. To be eligible for this study, you must be the mother to a child with Anorexia and currently be in a committed relationship. If your child is between the ages of 10-21, is currently receiving outpatient treatment for Anorexia Nervosa, and is currently living with you and your spouse/partner at home, we invite you to participate in this important study.Participation will involve: Completing the questionnaire online will take approximately 15-30 minutes. You will not be asked to provide your name at any time– Publications or presentations about the research findings will not include individual responses, only summary data on all participants will be presented. If you would like more information about this study, please contact Marissa Alexander at ude.mahdrof@rellimamb, or Dr. Merle Keitel at ude.mahdrof@letiekm.
To participate in this study, click on the following link: https://www.surveymonkey.com/s/6QPPY8
The Johns Hopkins Eating Disorders Program is seeking adults aged 18-55 to participate in a placebo-controlled trial to examine the effectiveness of a research medication in the treatment of anorexia nervosa. Participants will be offered 16 weeks of medication (active or inactive) and weekly outpatient medical monitoring by a psychiatrist. The treatment will be provided at no cost and participants will receive up to $250 for completing all parts of the study. To participate, you must have anorexia nervosa, be 18-55 years old, be medically stable for outpatient treatment, and willing to complete assessments (interviews, questionnaires and medical evaluations) at intervals throughout the 16-week study and at 1- and 2-month follow-ups. All information gathered will remain confidential. Please call Angela Guarda (410) 955-3863 for more information or visit http://www.hopkinsmedicine.org/psychiatry/specialty_areas/eating_disorders/research.html.
Detailed Description:
The purpose of this pilot investigation is to assess AN interoceptive sensitivity and responsivity as it pertains to heart rate during exercise. Thirty adults, 18 years and older will be recruited for a cross-sectional comparison of IS and IR in the context of exercise.
Eligibility
Ages Eligible for Study: 18 Years to 35 Years
Genders Eligible for Study: Both
Accepts Healthy Volunteers: Yes
Criteria
Inclusion Criteria: Study participants will include adults with anorexia spectrum disorders and healthy age and gender matched controls. There will be two control groups, one that includes regularly exercising age and gender matched persons and one where controls do not engage in regular exercise.
For those with AN, the following INCLUSION criteria must be met:
Age 18 to 35 years
BMI 25 kg/m2 or less
Diagnosis of anorexia spectrum disorder
Medications: Stable use of all medications ≥ three months
For age and gender matched controls, the following INCLUSION criteria must be met:
Age 18 to 35 years
BMI 25 kg/m2 or less
No diagnosis of anorexia spectrum disorder
Medications: Stable use of all medications ≥ three months
Age (+/- 2 years) and gender matched to study participant
Exclusion Criteria:
History of diabetes, heart disease or taking medications for those conditions
History of hypertension (high blood pressure) not controlled with medication
Orthopedic limitations, musculoskeletal disease and/or injury
Inability to consent
Lack of transportation to the Duke Center for Living campus
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT02579018
Contacts
Contact: Lucy W Piner, MS 919-660-6781 ude.ekud.md@renip.ycul
Contact: Kim M Huffman, MD 919-668-1644 ude.ekud.md@namffuh.mik
Locations
United States, North Carolina
Duke Medicine – Duke Molecular Physiology Institute Recruiting
Durham, North Carolina, United States, 27705
Contact: Lucy W Piner, MS 919-660-6781 ude.ekud@renip.ycul
Principal Investigator: Kim M Huffman, MD
Principal Investigator: Nancy Zucker, PhD
Sponsors and Collaborators
Duke University
Investigators
Principal Investigator: Nancy L Zucker, PhD Director, Duke Center for Eating Disorders
More Information
Responsible Party: Duke University
ClinicalTrials.gov Identifier: NCT02579018 History of Changes
Other Study ID Numbers: Pro00064421
Study First Received: October 15, 2015
Last Updated: March 15, 2016
Health Authority: United States: Institutional Review Board
Graduate student at Richmont Graduate University is conducting a study aimed at distinguishing how religious coping methods and views of God’s grace affect and interact with Anorexia Nervosa.
WHO CAN PARTICIPATE?
Males and females age 18 or older who:
claim Christianity as their religion;
have been diagnosed with Anorexia Nervosa;
care read at the 6th grade level; AND
are willing to spend 20 to 35 minutes answering questions on online questionnaires.
WHERE?
To participate in the study, please visit the following website:
WHAT WILL HAPPEN?
Complete five online questionnaires at your own pace, on your own time, and in the comfort of your own home!
No identifying information will be requested.
This study has received approval from the Richmont Graduate University Human Subjects Committee. Primary investigators for this study are DeAnne Terrell, Ph.D., Dean of Students, Richmont Graduate University, and Katie Rider, BA, Master of Arts in Professional Counseling student, Richmont Graduate University.
For more information, please visit the following website http://www.mannafund.org or contact Katie Rider at 678-235-5917 or moc.liamg@hcraeserecargana.
raduate student at Richmont Graduate University is conducting a study aimed at distinguishing how religious coping methods and views of God’s grace affect and interact with Anorexia Nervosa.
WHO CAN PARTICIPATE?
Males and females age 18 or older who:
claim Christianity as their religion;
have been diagnosed with Anorexia Nervosa;
care read at the 6th grade level; AND
are willing to spend 20 to 35 minutes answering questions on online questionnaires.
WHERE?
To participate in the study, please visit the following website:
WHAT WILL HAPPEN?
Complete five online questionnaires at your own pace, on your own time, and in the comfort of your own home!
No identifying information will be requested.
This study has received approval from the Richmont Graduate University Human Subjects Committee. Primary investigators for this study are DeAnne Terrell, Ph.D., Dean of Students, Richmont Graduate University, and Katie Rider, BA, Master of Arts in Professional Counseling student, Richmont Graduate UniThe UNC Center of Excellence for Eating Disorders is studying two different treatments intended to help couples in which one partner has a diagnosis of Anorexia Nervosa (AN). Eligible couples will receive 23 weeks of study-related treatment from the UNC Center of Excellence for Eating Disorders team at no cost and payment for participating in additional assessments. If you are 18 years or older, married or have been in a committed relationship with your partner for at least 6 months, and currently live together, you may be eligible. One partner must have a diagnosis of AN, and both partners must speak English. All research related therapy and evaluations are offered at no cost.
More information is available at http://www.unceatingdisorders.org. Please contact the research coordinator, Kate Nowlan, at 919-843-2483 or email ude.cnu@nacu for more information.
919-843-2483
http://www.unceatingdisorders.org
ude.cnu@nacu
versity.
For more information, please visit the following website http://www.mannafund.org or contact Katie Rider at 678-235-5917 or moc.liamg@hcraeserecargana.
The Neuroendocrine Unit at Massachusetts General Hospital is offering a variety of research studies for women with anorexia nervosa. We are currently researching different methods of treatment for bone loss, anxiety & depression, and gastrointestinal issues in women with anorexia nervosa. If you are interested in participating, take this brief pre-screening survey – https://redcap.partners.org/redcap/surveys/?s=7D5MTI
Massachusetts General Hospital Neuroendocrine Unit
(617) 724-7129
gro.srentrap@notrohes
Project Name: Qsymia (phentermine-topiramate) to Reduce Binge Eating/Purging in Patients with Binge Eating Disorder and Bulimia Nervosa
Project Description: This study aims to test the efficacy of an FDA approved drug for obesity, Qsymia, for reducing symptoms of binge eating and/or purging in participants with binge eating disorder and bulimia nervosa, compared to a control medication. All study participants will receive the study medication– either in the first half of the study or in the second half of the study. Neither you nor members of the research team will know the order in which you receive them until the end of the trial. Medication is provided at no cost and the study is expected to take up to 6 months.
Who can participate? Men and women aged 18-60 with current symptoms of binge eating and/or purging
For more information: Please contact Hannah at ude.drofnats@amayoth or at (650)-723-2242.
Are You between the Ages of 18-40 and Struggling with Anorexia Nervosa or a Related Eating Disorder Marked by Food Restriction and Weight Loss? You may qualify to be in a research study of a new Multifamily Therapy Group Treatment for Adults (ages 18-40) with Anorexia Nervosa.
The University of Rochester School of Nursing is conducting a clinical study evaluating this new treatment involving the individual with the eating disorder and their identified family members. Family members can be adult (> 18) family of origin members like parents and siblings or adult (> 18) “family of choice” members like partners, close friends, and mentors.
If you are interested, contact the University of Rochester School of Nursing at (585) 275-6629 to see if you qualify.
Purpose
The investigators are examining what types of psychotherapy are most helpful for patients as they undergo weight restoration treatment for anorexia nervosa. In this study, patients who are receiving care on our inpatient unit will also receive 4 weeks of one two types of psychotherapy: Supportive Psychotherapy or Regulation Emotions and Changing Habits.
Detailed Description:
Patients will be receiving specialized inpatient treatment for anorexia nervosa on the Eating Disorders Unit at the New York State Psychiatric Institute, where care is provided free of charge.
Study procedures will begin after one week of acclimating to the inpatient unit. Patients will be randomly assigned to receive either Supportive Psychotherapy (focused on the transition to the inpatient unit) or REACH (focused on changing routines or habits that have become part of the eating disorder). Each treatment consists of 12-sessions, delivered 2-3 times per week.
Before and after treatment, patients will be asked to participate in interviews, questionnaires, and a lunch meal.
Eligibility
Ages Eligible for Study: 18 Years to 45 Years
Genders Eligible for Study: Both
Accepts Healthy Volunteers: No
Criteria
Inclusion Criteria:
DSM5 diagnosis of anorexia nervosa
Age>= 18
Medically stable
Able to provide informed consent
Exclusion Criteria:
Other psychiatric disorder requiring acute treatment
Serious medical illness
Antipsychotic medication
Severe cognitive impairment
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT02382055
Contacts
Contact: Gabriella Guzman 646-774-8066
Contact: Joanna Steinglass, MD
Locations
United States, New York
New York State Psychiatric Institute Recruiting
New York, New York, United States, 10032
Contact: Joanna Steinglass, MD 646-774-6345 ude.aibmuloc@4211sj
Principal Investigator: Joanna Steinglass, MD
Sponsors and Collaborators
New York State Psychiatric Institute